Tumor cells with defective type I interferon signaling and antiviral responses

Tumor cells with defective type I interferon (IFN) signaling and antiviral responses represent a specific cellular phenotype characterized by the inability to mount an innate immune defense against viral pathogens. This defect often arises through mutations or epigenetic silencing of key pathway components such as JAK1, STAT1, or the IFNAR receptors, which normally mediate the production and response to IFN-alpha and IFN-beta (Zitvogel et al., 2015, Nature Reviews Immunology). While these defects allow tumors to evade immune surveillance and growth inhibition, they also create a unique therapeutic vulnerability. Oncolytic viruses, such as Talimogene laherparepvec (T-VEC) and various vesicular stomatitis virus (VSV) constructs, are designed to exploit this weakness by selectively replicating within and lysing these IFN-deficient cells while being cleared by the intact antiviral responses of healthy tissues (Lichty et al., 2014, Nature Reviews Cancer). This selective oncolysis not only destroys the primary tumor but also releases tumor-associated antigens, potentially stimulating a systemic anti-tumor immune response. Consequently, the status of the type I IFN pathway serves as both a selective "target" for viral therapy and a critical biomarker for predicting patient response to oncolytic treatments.

Other names

IFN-deficient tumor cellsType I IFN signaling-deficient cancer cellsAntiviral-deficient tumor cellsIFN-non-responsive tumor cells

Selective viral replication and oncolysis in cells with impaired innate antiviral immunity